News release

TOKYO, JAPAN - May 14, 2021 - As the world joins together to fight the ongoing battle against the COVID-19 pandemic, Terumo Corporation (TSE: 4543) has announced that the Terumo Group companies will collectively donate USD 1 million in cash to support the COVID-19 Solidarity Response Fund for the World Health Organization (WHO). Terumo has already donated USD 1 Million in April 2020, and this is the company's second time aiding the fund.
The fund, managed by the WHO Foundation, marked its first anniversary this March. So far, the donations collected from companies and individuals globally has supported WHO to mobilize nearly USD 250 million; into research for vaccines and tests, to share accurate scientific guidance to prevent infections, and to provide lifesaving supplies to those in need.
In addition to the current relief efforts, there is a new focused need for vaccine equity. Vaccine administrations have begun across the world, however low-income countries have received less than 1% of all of the vaccines administered worldwide. The new donation will aid WHO to contribute to vaccine equity broadly, and to other pressing needs for COVID-19 treatments, diagnostics, PPE distribution, and health system strengthening.
Shinjiro Sato, President and CEO of Terumo commented, "Healthcare is a fundamental human right, and as a medical device company we believe in equality of healthcare. We are honored to contribute to help those in need to get the necessary care and protection, and ultimately do what's right for the world."
About Terumo
Terumo (TSE: 4543) is a global medical innovation company. Guided by an unwavering commitment to patients, and driven by the passion of our associates, we strive to fulfill our Group Mission of “Contributing to Society through Healthcare.” Founded in Tokyo in 1921, we provide a comprehensive range of solutions in the fields of therapeutic procedures, hospital operations, and life sciences in more than 160 countries and regions.